Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (greater than or equal to 66 years) previously vaccinated with the same candidate vaccine. Fluarix will be used as reference.

Trial Profile

Reactogenicity and immunogenicity of GSK Biologicals' influenza vaccine GSK576389A in elderly adults (greater than or equal to 66 years) previously vaccinated with the same candidate vaccine. Fluarix will be used as reference.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs GSK 576389A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 07 Sep 2008 Actual patient number (133) added as reported by ClinicalTrials.gov.
    • 29 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top